BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34399996)

  • 21. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Diamand R; Ploussard G; Roumiguié M; Oderda M; Benamran D; Fiard G; Quackels T; Assenmacher G; Simone G; Van Damme J; Malavaud B; Iselin C; Descotes JL; Roche JB; Peltier A; Roumeguère T; Albisinni S
    Eur Urol; 2021 Feb; 79(2):180-185. PubMed ID: 33023770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
    Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
    Sandeman K; Eineluoto JT; Pohjonen J; Erickson A; Kilpeläinen TP; Järvinen P; Santti H; Petas A; Matikainen M; Marjasuo S; Kenttämies A; Mirtti T; Rannikko A
    PLoS One; 2020; 15(7):e0235779. PubMed ID: 32645056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement.
    Pak S; Lee DE; You D; Jeong IG; Joung JY; Lee KH; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2021 May; 39(5):298.e1-298.e6. PubMed ID: 33579626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
    Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
    Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
    Parker R; Bell A; Chang K; Greenberg S; Washington SL; Cowan JE; Carroll PR; Cooperberg MR
    Prostate; 2023 Jul; 83(10):922-928. PubMed ID: 37078628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
    Dell'Oglio P; Suardi N; Boorjian SA; Fossati N; Gandaglia G; Tian Z; Moschini M; Capitanio U; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
    Eur J Cancer; 2016 Feb; 54():27-34. PubMed ID: 26707594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Nomogram to Identify Candidates for Focal Therapy Among Patients with Localized Prostate Cancer Diagnosed via Magnetic Resonance Imaging-Targeted and Systematic Biopsies: A European Multicenter Study.
    Mjaess G; Peltier A; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; Nguyen TA; Fournier G; Fiard G; Ploussard G; Roumeguère T; Albisinni S; Diamand R
    Eur Urol Focus; 2023 Nov; 9(6):992-999. PubMed ID: 37147167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimising preoperative risk stratification tools for prostate cancer using mpMRI.
    Reisæter LAR; Fütterer JJ; Losnegård A; Nygård Y; Monssen J; Gravdal K; Halvorsen OJ; Akslen LA; Biermann M; Haukaas S; Rørvik J; Beisland C
    Eur Radiol; 2018 Mar; 28(3):1016-1026. PubMed ID: 28986636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
    Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of biochemical recurrence after laparoscopic radical prostatectomy.
    Bejrananda T; Pliensiri P
    BMC Urol; 2023 Nov; 23(1):183. PubMed ID: 37953250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort.
    Thederan I; Chandrasekar T; Tennstedt P; Knipper S; Kuehl L; Tilki D; Augustin M; Heinzer H; Zyriax BC
    Eur Urol Focus; 2021 Sep; 7(5):973-979. PubMed ID: 33408047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in intermediate-risk patients.
    Baboudjian M; Uleri A; Beauval JB; Touzani A; Diamand R; Roche JB; Lacetera V; Lechevallier E; Roumeguère T; Simone G; Benamran D; Fourcade A; Fiard G; Peltier A; Ploussard G
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):318-322. PubMed ID: 37452146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A nomogram predicting long-term biochemical recurrence after radical prostatectomy.
    Suardi N; Porter CR; Reuther AM; Walz J; Kodama K; Gibbons RP; Correa R; Montorsi F; Graefen M; Huland H; Klein EA; Karakiewicz PI
    Cancer; 2008 Mar; 112(6):1254-63. PubMed ID: 18286530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.